D. E. Shaw & Co., Inc. Theravance Biopharma, Inc. Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 833,943 shares of TBPH stock, worth $7.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

833,943

Previous 764,765 9.05%

Holding current value

$7.8 Million

Previous $6.16 Million 27.3%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$7.93 - $10.08 $548,581 - $697,314	69,178 Added 9.05%	833,943 $7.85 Million
Q3 2024 Nov 14, 2024	BUY	$7.66 - $10.25 $51,207 - $68,521	6,685 Added 0.88%	764,765 $6.16 Million
Q2 2024 Aug 14, 2024	SELL	$8.29 - $9.92 $194,856 - $233,169	-23,505 Reduced 3.01%	758,080 $6.43 Million
Q1 2024 May 15, 2024	SELL	$8.22 - $11.59 $572,301 - $806,930	-69,623 Reduced 8.18%	781,585 $7.01 Million
Q4 2023 Feb 14, 2024	BUY	$8.58 - $11.4 $1.39 Million - $1.84 Million	161,647 Added 23.44%	851,208 $9.57 Million
Q3 2023 Nov 14, 2023	SELL	$8.38 - $10.44 $205,754 - $256,333	-24,553 Reduced 3.44%	689,561 $5.95 Million
Q2 2023 Aug 14, 2023	SELL	$10.16 - $11.92 $3.06 Million - $3.59 Million	-300,879 Reduced 29.64%	714,114 $7.39 Million
Q1 2023 May 15, 2023	SELL	$9.87 - $11.44 $5.5 Million - $6.38 Million	-557,657 Reduced 35.46%	1,014,993 $11 Million
Q4 2022 Feb 14, 2023	SELL	$9.65 - $11.34 $140,388 - $164,974	-14,548 Reduced 0.92%	1,572,650 $17.6 Million
Q3 2022 Nov 14, 2022	BUY	$8.39 - $10.22 $1.74 Million - $2.11 Million	206,801 Added 14.98%	1,587,198 $16.1 Million
Q2 2022 Aug 15, 2022	BUY	$8.41 - $10.34 $1.19 Million - $1.46 Million	141,355 Added 11.41%	1,380,397 $12.5 Million
Q1 2022 May 16, 2022	BUY	$8.33 - $12.96 $3.02 Million - $4.7 Million	362,579 Added 41.37%	1,239,042 $11.8 Million
Q4 2021 Feb 14, 2022	BUY	$7.42 - $11.05 $3.39 Million - $5.04 Million	456,412 Added 108.66%	876,463 $9.68 Million
Q3 2021 Nov 15, 2021	BUY	$6.77 - $14.41 $2.84 Million - $6.05 Million	420,051 New	420,051 $3.11 Million
Q2 2021 Aug 16, 2021	SELL	$14.52 - $22.46 $813,323 - $1.26 Million	-56,014 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.57 - $21.08 $347,207 - $441,710	20,954 Added 59.77%	56,014 $1.14 Million
Q4 2020 Feb 16, 2021	SELL	$14.89 - $20.16 $505,828 - $684,855	-33,971 Reduced 49.21%	35,060 $623,000
Q3 2020 Nov 16, 2020	SELL	$14.79 - $22.49 $88,636 - $134,782	-5,993 Reduced 7.99%	69,031 $1.02 Million
Q2 2020 Aug 14, 2020	BUY	$20.64 - $30.69 $1.36 Million - $2.03 Million	66,073 Added 738.16%	75,024 $1.58 Million
Q1 2020 May 15, 2020	SELL	$17.84 - $31.21 $171,049 - $299,241	-9,588 Reduced 51.72%	8,951 $207,000
Q2 2019 Aug 14, 2019	SELL	$15.6 - $25.15 $254,779 - $410,749	-16,332 Reduced 46.84%	18,539 $303,000
Q1 2019 May 15, 2019	SELL	$22.57 - $28.15 $906,478 - $1.13 Million	-40,163 Reduced 53.53%	34,871 $791,000
Q4 2018 Feb 14, 2019	BUY	$22.52 - $35.07 $537,890 - $837,646	23,885 Added 46.7%	75,034 $1.92 Million
Q3 2018 Nov 14, 2018	BUY	$22.83 - $32.67 $341,787 - $489,102	14,971 Added 41.38%	51,149 $1.67 Million
Q2 2018 Aug 14, 2018	SELL	$22.06 - $25.52 $809,403 - $936,354	-36,691 Reduced 50.35%	36,178 $821,000
Q1 2018 May 15, 2018	SELL	$23.37 - $29.71 $343,889 - $437,182	-14,715 Reduced 16.8%	72,869 $1.77 Million
Q4 2017 Feb 14, 2018	SELL	$25.82 - $35.66 $84,276 - $116,394	-3,264 Reduced 3.59%	87,584 $2.44 Million
Q3 2017 Nov 14, 2017	BUY	$23.88 - $34.96 $2.17 Million - $3.18 Million	90,848	90,848 $3.11 Million

Others Institutions Holding TBPH

# of Institutions

129

Shares Held

46.5M

Call Options Held

600

Put Options Held

300

View Full List

About Theravance Biopharma, Inc.

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $624M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

More about TBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account